Newron Pharmaceuticals S.p.A. (NWPHF) Discusses FDA Clinical Hold and Safety Concerns in ENIGMA-TRS Program for Treatment-Resistant Schizophrenia Transcript

Newron Pharmaceuticals' FDA clinical hold on its treatment-resistant schizophrenia drug has raised concerns about the company's safety protocols.

The company is working with the FDA to address the issues and resume clinical trials.